Latest news with #Delphi
Yahoo
2 days ago
- Business
- Yahoo
‘The Studio' acting Emmy submissions revealed — including guest stars Martin Scorsese, Sarah Polley, and Bryan Cranston
Apple TV+ has revealed its Emmy acting submissions for its breakout comedy series The Studio, including its lengthy list of guest actors. As expected, the show's only lead acting submission is star Seth Rogen, who plays the newly hired head of the fictional Continental Studios in the Hollywood satire. More from GoldDerby Michael B. Jordan expands 'Creed' universe with new Prime Video series 'Delphi' Here's your first look at 'Spider-Noir' starring Nicolas Cage 'Fallout' gets early Season 3 renewal ahead of Season 2 premiere in December The show's other main cast members will run in the supporting categories: Ike Barinholtz and Dewayne Perkins in Best Comedy Supporting Actor, and Kathryn Hahn, Keyla Monterroso Mejia, Catherine O'Hara, and Chase Sui Wonders in Best Comedy Supporting Actress. Cocreated by Rogen and Evan Goldberg, as well as Peter Huyck and Alex Gregory (Veep) and Frida Perez, The Studio's first season tracks Matt's ups and downs on the job, including having to tell Martin Scorsese (as himself) that his planned movie about Jonestown was being scrapped. Significant Hollywood filmmakers play themselves in the series, including Scorsese, Sarah Polley, Ron Howard, Nicholas Stoller, Zoë Kravitz, and Olivia Wilde. All those directors will be submitted on the Emmys ballot for guest consideration for The Studio alongside actors Anthony Mackie, Zac Efron, Dave Franco, and Greta Lee, who also play themselves. Other guest submissions for The Studio include real actors playing fictional characters: Bryan Cranston (who plays Griffin Mill, the CEO of Continental Studios), David Krumholtz (who plays a foul-mouthed agent), and Rebecca Hall (who plays a successful doctor who embarks on a failed relationship with Matt). The final guest-acting submission for Apple is journalist Matt Belloni. The Puck cofounder and The Town podcast host appears in multiple episodes of The Studio, both as a voice performer (through a fictional episode of his podcast) and live-action actor (on the casino floor during CinemaCon). These are just the names Apple is submitting on the Emmy ballot; anyone else, perhaps guest stars Parker Finn or Adam Scott, can submit on their own. Apple TV+ recently renewed The Studio for Season 2. The show's first season ends later this month. Best of GoldDerby 'The Better Sister' showrunner Regina Corrado: Jessica Biel and Elizabeth Banks 'are at the top of their game' Danielle Pinnock on playing Alberta in CBS' 'Ghosts,' representation, and what's next for the hit comedy 'I didn't think he was a jerk': Paul Giamatti on finding the humanity in his standout 'Black Mirror' episode Click here to read the full article.
Yahoo
4 days ago
- Health
- Yahoo
Long Covid campaigner co-authors ground-breaking international study
A LONG Covid campaigner has co-authored a new study highlighting the seriousness of the condition. Sammie McFarland, from Weymouth, said she was 'honoured' to contribute to a landmark international study which confirms the condition is debilitating, and the global response must be drastically scaled up. The Delphi study, involving more than 150 experts across medicine, research, and patient advocacy, represents a first-of-its-kind consensus on the priorities, gaps, and urgent needs surrounding Long Covid. It comes after the news that Covid services throughout England - including Dorset - are being scrapped. Mrs McFarland, has been at the forefront of campaigning to raise awareness of the condition, that she and her daughter live with, and set up the Long Covid Kids charity to support children living with the condition. She said: "As a Dorset resident and founder of Long Covid Kids, I was honoured to contribute to this newly published international consensus on Long Covid. "Bringing together perspectives from over 150 experts across 28 countries including clinicians, researchers, and people with lived experience. "This study represents a significant step forward in how we understand and respond to this complex condition. READ: Dorset Long Covid campaigner backs NHS doctors plan to sue "Long Covid affects hundreds of millions of people around the world, including many children and young people. Yet too often, it remains under-recognised and under-resourced. "Through this work, we reached consensus on nearly 190 recommendations to guide better diagnosis, treatment, research, and support." Mrs McFarland is a vocal advocate of children suffering with the debilitating condition and through her charity has sought to improve the support network for children and their families. She said that new study concluded that the impact of Covid-19 on children 'must be a research priority' from understanding the long-term health effects to supporting learning, development, and mental wellbeing. READ: Weymouth woman's fight against long Covid amid inquiry She added: "This consensus is more than a scientific document. It's a foundation for action to improve care, guide policy, and provide the clarity that so many families have been waiting for. "Here in Dorset and across the UK, children and families affected by Long Covid deserve to be seen, heard, and supported - as with any significant childhood disease.' The study identified ten critical areas requiring immediate action. This includes educating frontline providers to recognize Long COVID as a complex, multi-system condition involving neurological, immune, and organ dysfunction READ: Weymouth mother develops resource for kids with long Covid It also says that a universal definition for the condition should be created and that the condition should not just be recognised as 'tiredness' but includes serious complications such as immune dysregulation, neurological injury, and organ damage. The study also concludes that Long Covid is an invisible disability and that current diagnostics fall short due to lab limitations, with advanced diagnostics needed as it is not one disease, but a cluster of overlapping conditions. Experts also emphasized the need for long-term studies on how SARS-CoV-2 affects developing immune systems, brains, and hormonal balance as children are as much at risk to the condition. READ: Weymouth Long Covid campaigner hits out at clinic closures Clean indoor air and reducing airborne transmission of the virus through improved ventilation and air purification - particularly in schools and workplaces - is also essential for public health infrastructure, it concludes. Finally experts came to the consensus that Long Covid requires coordinated international funding and that it is not just a medical issue but a socioeconomic one and warns that continued inaction is a policy failure with long-term consequences.
Yahoo
21-05-2025
- Business
- Yahoo
Aduro Clean Technologies Engages Delphi for Life Cycle Assessment of Hydrochemolytic™ Technology
LONDON, Ontario, May 21, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. ('Aduro' or the 'Company') (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced that it has engaged Delphi, a leading Canadian sustainability consultancy, to conduct a Life Cycle Assessment ('LCA') of the Company's Hydrochemolytic™ technology for waste plastic processing. Delphi is a strategic consulting firm with 35 years of experience, specializing in corporate sustainability, climate change, the green economy, and cleantech innovation. The LCA is part of Aduro's strategic roadmap to independently assess and quantify the environmental performance of its chemical recycling platform through a phased, data-driven process. With increasing regulatory and market emphasis on measurable environmental outcomes, the LCA provides a foundation for engaging stakeholders with credible, third party-reviewed information. Additionally, the LCA will provide critical data to assist in identifying and minimizing inefficiencies and energy consumption throughout the process, assisting in maximizing resource efficiency and reducing operational costs. The project will begin with a screening-level LCA focused on greenhouse gas ('GHG') emissions and energy use, associated with operating the Hydrochemolytic™ technology process. This assessment, based on pre-pilot-scale performance data and forward-looking design parameters, will follow ISO 14040 and 14044 frameworks to provide directional insights into the technology's environmental profile. This phase will lay the groundwork for future work as more detailed data becomes available. The screening assessment will support Aduro's broader efforts to align its innovation strategy with the performance expectations of regulators, customers, and investors in the circular economy. Subsequent phases of the LCA will incorporate operational data from the Company's Next Generation Process ('NGP') pilot plant, which is currently under construction. The second phase will provide a more comprehensive, ISO-compliant assessment of all relevant life cycle stages, including feedstock sourcing and downstream product pathways. A final phase is anticipated to support a comparative LCA, benchmarking the Hydrochemolytic™ process against other chemical recycling approaches. 'As we continue to focus on our commercial path, we are starting the preparation to assess the NGP pilot plant for its environmental performance and impact. Delphi is a highly reputable organization and is an ideal partner to perform the LCA work to assess and quantify the Hydrochemolytic™ technology's performance and its ability to support decarbonization,' said Ofer Vicus, CEO of Aduro. 'The outcomes from this work will inform our stakeholders with a transparent and data-driven view of our environmental profile and help position our technology as a viable solution for tackling plastic waste.' 'Our goal is to deliver a robust, independent assessment of the environmental impacts and benefits of Aduro's process,' said Stephan Wehr, Vice President, Climate Change at Delphi. 'The phased approach provides flexibility and responsiveness to available data while adhering to LCA best practices. Having supported LCA work on other chemical recycling processes, including pyrolysis, we see this as an important opportunity to highlight how alternative pathways like Hydrochemolysis may demonstrate a distinct environmental profile—particularly in terms of GHG emissions and energy intensity.' About Delphi Delphi is a Canadian strategic consultancy specializing in climate change, sustainability, and environmental, social, and governance (ESG) advisory services. With over 35 years of experience, Delphi provides practical, actionable advice and roadmaps to help organizations navigate uncertainty, manage risk, and enhance competitiveness. As a Certified B Corporation, Delphi meets high standards of social and environmental performance, transparency, and accountability. Delphi is part of Profoundry, a collective of sustainability experts and organizations, including GLOBE Series, CBSR, and Leading Change Canada, dedicated to accelerating and showcasing sustainable performance across Canada. About Aduro Clean Technologies Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company's Hydrochemolytic™ Technology relies on water as a critical agent in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into resources for the 21st century. For further information, please contact: Abe Dyck, Head of Business Development and Investor Relationsir@ 226 784 8889 KCSA Strategic CommunicationsJack Perkins, Senior Vice Presidentaduro@ news release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information relates to future events or future performance and reflects the expectations or beliefs of management of Aduro Clean Technologies Inc. ('Aduro' or the 'Company') regarding future events. In certain cases, forward-looking information can be identified by the use of words such as 'plans', 'expects', 'estimates', 'intends', 'anticipates', 'believes' or variations of such words or statements that certain actions, events or results 'may', 'could', 'would', 'might', or 'will' be taken, occur or be achieved. Forward-looking information in this news release includes, but is not limited to, statements with respect to the planned commencement and completion of a screening-level Life Cycle Assessment (LCA); the scope and timing of future LCA phases; the use of pilot-scale data in subsequent assessments; the conformance of future assessments with ISO 14040 and 14044 standards; the anticipated commissioning of the Company's pilot plant; the expectation that the results of the LCA will inform comparative performance evaluations and support the Company's commercialization efforts; the engagement of Delphi to conduct the LCA of the Hydrochemolytic™ technology ('HCT'); the expectation that Delphi's assessment will provide credible, third-party-reviewed environmental performance data; the anticipated benefits of the LCA in supporting stakeholder engagement, identifying inefficiencies, reducing costs, and improving resource efficiency; and the belief that the Company's technology is positioned as a viable solution for tackling plastic waste and supporting decarbonization, including assumptions about future market acceptance and environmental performance validation. Forward-looking information is based on assumptions, estimates, projections, opinions, and analyses made by management in light of its experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances. While the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, such information involves known and unknown risks, uncertainties, and other factors and should not be unduly relied upon. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the LCA may not yield favorable results; the uncertainty around the completeness or accuracy of pre-pilot data used in the assessment; risks related to the use of the LCA for stakeholder engagement and operational efficiency, including the possibility that stakeholders may not accept or value the LCA findings, or that operational improvements may not materialize as expected; risks associated with the phased LCA approach, including the dependency on the availability and quality of pilot plant data and the potential for regulatory or methodological changes to affect the LCA framework or comparability; risks related to the construction and operation of the NGP pilot plant, including delays, technical issues, or performance outcomes that may not reflect commercial-scale viability; and risks related to the positioning of HCT as a decarbonization solution, including slower-than-anticipated market adoption, superior performance by competing technologies, or regulatory changes that could shift incentives or requirements. Furthermore, actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's pilot plant may be delayed or not commissioned as expected; that the Company may not be able to generate or collect the necessary data for future LCA phases; that regulatory or methodological changes may negatively affect LCA outcomes; or that market conditions or third-party review processes may delay or alter the Company's plans. The Company disclaims any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by law.A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
16-05-2025
- Entertainment
- Newsweek
Michael B. Jordan Producing Creed Series for Prime Video.
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Entertainment gossip and news from Newsweek's network of contributors The first Creed spinoff series is entering production at Prime Video. The upcoming drama, titled Delphi, follows fledgling boxers training at the fictional Delphi gym. Michael B. Jordan and his company Outlier Society are producing the series, which is currently a Prime Video exclusive. According to reports, Outlier Society currently has a first-look film deal at Amazon MGM Studios, meaning if the show performs well it could lead to a big screen crossover. Michael B. Jordan stars in Creed 3 Michael B. Jordan stars in Creed 3 MGM The Creed trilogy, itself an offshoot of the six-film Rocky franchise, debuted in 2015. It follows Adonis Creed (Michael B. Johnson), the son of Rocky's first rival, Apollo Creed. Over the trilogy, we follow his rise from juvenile delinquent to world boxing champion, defeating his opponents and battling personal demons. Creed Box Office Creed has grossed over $660 million worldwide across three films, with each film increasing the box office earnings. Here's how much each Creed film has made. Creed (2015) - $174.2 million Creed II (2018) - $213.6 million Creed III (2023) - $276.1 million Delphi Boxing Academy, to give it its full title, exists in both the Rocky and Creed series. Operating out of Los Angeles, California, it was founded by Tony 'Duke' Evers, who trained the Apollo Creed there. Duke's son Tony Evers inherited the gym, and trained the son of Apollo Creed, Adonis Johnson Creed. Adonis is still at Delphi to this day, where he holds the WBC Heavyweight title. Delphi, which will air on Prime Video in 240 countries and territories, already has its showrunner and executive producer in Marco Ramirez. He previously acted as showrunner on another boxing drama: Hulu's La Máquina starring Gael Garcia Bernal, Diego Luna, and Eiza González. Outlier Society, meanwhile, is also developing a Muhammad Ali series called The Greatest. Delphi Release Date There is currently no release date for Delphi, but don't expect it any earlier than 2028.
Associated Press
15-05-2025
- Health
- Associated Press
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
WESTLAKE VILLAGE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients in the Journal of the European Academy of Dermatology and Venereology (JEADV) Clinical Practice. The consensus statements are aimed at providing expert, multidisciplinary guidance in three key areas: (1) physical diagnosis and patient conversations, (2) impact on quality of life and interpersonal relationships, and (3) treatment decisions. 'Despite affecting an estimated six million Americans, genital psoriasis is often underreported and undertreated due to the uniquely sensitive and private nature of the afflicted areas, and uncertainty for how to begin the conversation. Relative to psoriasis in other areas of the body, genital psoriasis also has a greater impact on psychological well-being and quality of life, interpersonal relationships, intimacy, feelings of stigmatization, and rates of depression,' said Jennifer C. Cather, MD, FAAD, Medical Director and Founder of Mindful Dermatology and Modern Research Associates in Dallas, Texas, Genital Psoriasis Consortium member, and manuscript author. 'With the current lack of formal guidelines around genital psoriasis, the goal of convening the Consortium was to bridge the gaps in clinician-patient communication, develop tools and processes that aid in identification and diagnosis, and better-informed shared treatment decisions.' To formulate the consensus statements, a PubMed literature search was conducted, and a total of 78 unique publications were reviewed. Consortium members used a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings focused on the three key areas, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations. 'Normalizing conversations and improving shared decision-making are critical first steps to improving outcomes. Implementation of the Consortium's new guidelines could provide consistent, streamlined care practices that don't currently exist for this condition,' said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis. 'Arcutis is proud to support the Consortium's efforts to challenge the status quo to improve care for those with genital psoriasis.' Below are the 14 consensus statements outlined in the publication: About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis' unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit or follow Arcutis on LinkedIn, Facebook, Instagram, and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential real-world use results of ZORYVE foam and the potential for ZORYVE to advance the standard of care in plaque psoriasis, atopic dermatitis and seborrheic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the 'Risk Factors' section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. † Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. ‡ Subject to financial eligibility requirements. Other terms and restrictions apply. Contacts: Media Amanda Sheldon, Head of Corporate Communications [email protected] Investors Latha Vairavan, Chief Financial Officer [email protected]
